Additional investment in New Zealand health welcomed by pharma trade group
New Zealand Prime Minister John Key yesterday announced a number of new initiatives which came to an investment of NZ$101 million ($79.5 million) over four years which will be largely funded by an increase in prescription charges and other savings within the health sector.
Reallocation of funding to allow better use of the nation’s health dollar has been something that pharma trade group Medicines New Zealand has long advocated for. “Raising the prescription fee for prescriptions to NZ$5 from January 2013 will make a positive contribution to supporting New Zealand’s health sector,” Medicines New Zealand general manager Kevin Sheehy says.
Recent Colmar Brunton research, commissioned by Medicines New Zealand in 2010, indicated that New Zealanders would feel comfortable paying between NZ$5 and NZ$9 for each prescription item, so this increase sits well within the realms of an acceptable increase.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze